Med24
peptide-development 1. 9. 2026 • 2 min read • Endocrinology, diabetes & metabolism

Impact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review

Background Cardiometabolic disorders such as type 2 diabetes mellitus (T2DM), obesity and cardiovascular disease (CVD) remain major global health challenges. Incretin-based therapies, including the GLP-1 receptor agonists semaglutide and liraglutide, and the dual GIP/GLP-1 receptor agonist tirzepatide, are...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

Cardiometabolic disorders, including type 2 diabetes mellitus, obesity, and cardiovascular disease, represent significant global health issues. Incretin-based therapies, specifically Semaglutide, Liraglutide, and Tirzepatide, are utilized to manage hyperglycaemia and obesity, and have been investigated for their impact on cardiometabolic risk markers and certain cardiovascular and renal outcomes.

Sponsored content

Key Clinical Findings

The studies evaluated the pharmacology of Semaglutide, Liraglutide, and Tirzepatide, differentiating between surrogate cardiometabolic risk markers such as glycaemic control, body weight, and lipid parameters, and confirmed clinical outcomes including major adverse cardiovascular events and renal endpoints. Recent data from trials like SUSTAIN, LEADER, and SURPASS/SURMOUNT, alongside meta-analyses and observational studies, were incorporated. Results indicated that all three agents improved HbA1c, weight, and cardiometabolic outcomes. Tirzepatide generally demonstrated greater reductions across clinical trials. Semaglutide and Liraglutide consistently improved BMI, lipid profile, and cardiovascular risk. Renal outcomes were favorable across the class, though results varied based on baseline characteristics and trial design.

Original Scientific Source
Endocrinology, diabetes & metabolism
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort
peptide-development

Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort

While GLP-1 and GIP receptor agonists like semaglutide and tirzepatide have revolutionized pharmacologic obesity treatment, metabolic and bariatric surgery (MBS) continues to demonstrate superior weight loss and cost-effectiveness. Current evidence shows tirzepatide outperforms semaglutide with over 20% weight...

1. 12. 2026 Read article →
Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation
peptide-development

Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved for cardiovascular risk reduction in individuals with overweight or obesity and cardiovascular disease. Whether tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist, has similar cardiovascular benefits...

10. 11. 2026 Read article →
The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome
peptide-development

The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome

Polycystic ovary syndrome (PCOS), recently renamed polyendocrine metabolic ovarian syndrome (PMOS), affects 170 million women globally and is often accompanied by obesity and various levels of insulin resistance. Incretin-based therapies, including the glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide and...

23. 10. 2026 Read article →
Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review
peptide-development

Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review

Cardiovascular-kidney-metabolic (CKM) syndrome reflects the complex interplay among cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity. GLP-1 receptor agonists and tirzepatide have emerged as important therapeutic options within CKM syndrome, although the strength and maturity of evidence...

16. 10. 2026 Read article →
Advertisement